Application of peripheral blood-derived stem cell (CD34?) therapy on chronic kidney disease

Application of peripheral blood-derived stem cell/progenitor cell (CD34?) therapy on chronic kidney disease: Phase 2 clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15592135

Enrollment

Registered

2018-08-22

Start date

2016-06-01

Completion date

Unknown

Last updated

2022-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease Urological and Genital Diseases Chronic kidney disease

Interventions

Participants will be evenly divided into the intervention group and the controlled group using the envelope method. Participants in the intervention group will receive standard medicat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 20-80 years old 2. Renal failure due to hypertension 3. Receiving optimal medical therapy (received optimal therapy for more than 12 weeks and have been evaluated by a nephrologist. Medication includes ACEI, ARB, DRI, beta-blocker or CCB. Blood pressure is less than 140/90 mmHg) 4. Renal function between chronic kidney disease (CKD) stage III-IV 5. Stable renal function maintained for 1 year before study (creatinine clearance rate between 15-60 ml/min and no significant changes)

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding 2. Infected with HIV 3. Infected with HBV or HCV 4. Myocardial infarction within 3 months prior to study 5. Heart failure (functional class IV) 6. Malignant or hematological disease 7. Severe disease with lifespan less than 1 year 8. End stage renal disease 9. Creatinine clearance rate less than 15 ml/min 10. Kidney disease on only one side 11. Participating in other clinical trials 12. Unable to receive therapies used in this study 13. Organ transplantation 14. Autoimmune disease

Design outcomes

Primary

Measure	Time frame
Improvement of Ccr (creatinine clearance rate cc/min) from the baseline, assessed using serum creatine levels at the baseline, and after 1 week and 1, 3, 6, 9 and 12 months	—

Secondary

Measure	Time frame
1. Reduction of proteinuria value (albumin/creatinine ratio), assessed at the baseline, and after 1 week and 1, 3, 6, 9 and 12 months. The albumin concentration per creatine level in urea is assessed using the microalbumin test and the urine protein/creatinine ratio is assessed by the Urine Protein-Creatinine Ratio (UPCR) test. 2. Incidence of renal failure (either requiring haemodialysis or causing death) within the 1 year follow-up period	—

Measure

Time frame

1. Reduction of proteinuria value (albumin/creatinine ratio), assessed at the baseline, and after 1 week and 1, 3, 6, 9 and 12 months. The albumin concentration per creatine level in urea is assessed using the microalbumin test and the urine protein/creatinine ratio is assessed by the Urine Protein-Creatinine Ratio (UPCR) test. 2. Incidence of renal failure (either requiring haemodialysis or causing death) within the 1 year follow-up period

—

Countries

Taiwan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026